Intarcia Therapeutics Inc. is eagerly awaiting a possible FDA approval of its diabetes implant, and its CEO Kurt Graves has said the company hopes to eventually go public.
Even as it approaches those milestones, the fast-growing biotech is making its presence felt on the South Boston waterfront.
Intarcia moved into a new 39,000-square-foot headquarters in the Fan Pier building last July. The space, which comprises nearly two floors at One Marina Park Drive, is much larger than its previous office…
Intarcia Therapeutics Inc. is eagerly awaiting a possible FDA approval of its diabetes implant, and its CEO Kurt Graves has said the company hopes to eventually go public.
Even as it approaches those milestones, the fast-growing biotech is making its presence felt on the South Boston waterfront.
Intarcia moved into a new 39,000-square-foot headquarters in the Fan Pier building last July. The space, which comprises nearly two floors at One Marina Park Drive, is much larger than its previous office…